INVO BIOSCIENCE INC (INVO) Stock Overview
USA - NASDAQ:INVO - US44984F4019 - Common Stock
INVO Key Statistics, Chart & Performance
The current stock price of INVO is 0.833 USD. In the past month the price increased by 20.13%. In the past year, price decreased by -35.92%.
INVO Latest News, Press Relases and Analysis
INVO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.11 | 218.08B | ||
| ISRG | INTUITIVE SURGICAL INC | 62.3 | 192.28B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.35 | 150.15B | ||
| SYK | STRYKER CORP | 28.91 | 142.04B | ||
| MDT | MEDTRONIC PLC | 16.54 | 117.29B | ||
| BDX | BECTON DICKINSON AND CO | 12.69 | 51.91B | ||
| IDXX | IDEXX LABORATORIES INC | 52.44 | 50.38B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.2 | 48.59B | ||
| RMD | RESMED INC | 26.63 | 37.12B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.38 | 34.32B | ||
| DXCM | DEXCOM INC | 40.36 | 26.91B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.34 | 26.43B |
Related stock screener links
About INVO
Company Profile
INVO BioScience, Inc. is a fertility company. The company is headquartered in Lakewood Ranch, Florida and currently employs 25 full-time employees. The company went IPO on 2008-11-11. The firm is focused on expanding the assisted reproductive technology (ART) marketplace by making fertility care accessible and inclusive to people around the world. The Company’s flagship product is INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. Its treatment solution is the intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. Its technique, designated as IVC, provides patients a more connected and intimate experience at a more affordable cost in comparison to in vitro fertilization (IVF), the other advanced ART treatment. Its commercialization strategy is focused on the opening of INVO Centers offering the INVOcell and IVC procedure and the acquisition of existing IVF clinics. The firm operates three INVO Centers in North America.
Company Info
INVO BIOSCIENCE INC
5582 Broadcast Ct
Lakewood Ranch FLORIDA 34240 US
CEO: Steven Shum
Employees: 25
Phone: 19788789505
INVO BIOSCIENCE INC / INVO FAQ
Can you describe the business of INVO BIOSCIENCE INC?
INVO BioScience, Inc. is a fertility company. The company is headquartered in Lakewood Ranch, Florida and currently employs 25 full-time employees. The company went IPO on 2008-11-11. The firm is focused on expanding the assisted reproductive technology (ART) marketplace by making fertility care accessible and inclusive to people around the world. The Company’s flagship product is INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. Its treatment solution is the intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. Its technique, designated as IVC, provides patients a more connected and intimate experience at a more affordable cost in comparison to in vitro fertilization (IVF), the other advanced ART treatment. Its commercialization strategy is focused on the opening of INVO Centers offering the INVOcell and IVC procedure and the acquisition of existing IVF clinics. The firm operates three INVO Centers in North America.
What is the current price of INVO stock?
The current stock price of INVO is 0.833 USD. The price decreased by -2.91% in the last trading session.
What is the dividend status of INVO BIOSCIENCE INC?
INVO does not pay a dividend.
How is the ChartMill rating for INVO BIOSCIENCE INC?
INVO has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the market capitalization of INVO stock?
INVO BIOSCIENCE INC (INVO) has a market capitalization of 3.26M USD. This makes INVO a Nano Cap stock.
Can you provide the upcoming earnings date for INVO BIOSCIENCE INC?
INVO BIOSCIENCE INC (INVO) will report earnings on 2024-11-11, after the market close.
INVO Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to INVO. When comparing the yearly performance of all stocks, INVO is a bad performer in the overall market: 85.67% of all stocks are doing better.
INVO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to INVO. INVO may be in some trouble as it scores bad on both profitability and health.
INVO Financial Highlights
Over the last trailing twelve months INVO reported a non-GAAP Earnings per Share(EPS) of -3.24. The EPS increased by 79.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -39.3% | ||
| ROE | -519.72% | ||
| Debt/Equity | 1.51 |
INVO Forecast & Estimates
6 analysts have analysed INVO and the average price target is 20.4 USD. This implies a price increase of 2348.98% is expected in the next year compared to the current price of 0.833.
For the next year, analysts expect an EPS growth of 50% and a revenue growth 199.65% for INVO